The various risk stratification schemes classified variable proportions as low , moderate and high risk , but the CHA(2)DS(2)-VASc score classified the smallest proportion of patients as ' low risk ' .
Anticoagulation with vitamin K antagonists and dabigatran is cost-effective in patients at high risk of stroke , but not in patients without any other stroke risk factor beside AF .
Risk factors for new thromboembolic stroke in patients > or = 62 years of age with chronic atrial fibrillation.
In a prospect i ve study of 312 older patients with chronic atrial fibrillation , at 36-month follow-up evaluation , new thromboembolic stroke developed in 162 of 312 patients ( 52 % ) . Significant independent risk factors for new thromboembolic stroke were prior stroke ( risk ratio = 1.6 ) , rheumatic mitral stenosis ( risk ratio = 2.0 ) , left ventricular ( LV ) hypertrophy ( risk ratio = 2.8 ) , abnormal LV ejection fraction ( risk ratio = 1.8 ) , serum total cholesterol ( risk ratio = 1.005 ) , and serum high-density lipoprotein cholesterol ( risk ratio = 0.96 )
The various risk stratification schemes classified variable proportions as low , moderate and high risk , but the CHA(2)DS(2)-VASc score classified the smallest proportion of patients as ' low risk ' .
Anticoagulation with vitamin K antagonists and dabigatran is cost-effective in patients at high risk of stroke , but not in patients without any other stroke risk factor beside AF .